Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pentavalent reassortant rotavirus attenuated live vaccine (Sinovac Biotech)
- Development stage
- Unknown
- Lead developer
- Sinovac Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
The pentavalent reassortant rotavirus attenuated live vaccine is an oral, live-attenuated biological product developed by Sinovac Life Sciences (a subsidiary of Sinovac Biotech). It is designed to prevent rotavirus gastroenteritis, a leading cause of severe diarrhea in infants and young children. The vaccine contains five reassortant rotavirus strains covering serotypes G1, G2, G3, G4, and G9, produced through reassortment between human and bovine rotavirus parent strains. It targets the outer capsid proteins VP7 and VP4 to induce a protective immune response. In clinical development, it has been used as an active comparator in trials for Sinovac's hexavalent rotavirus vaccine.
- Other names
- pentavalent rotavirus vaccineSinovac pentavalent rotavirus vaccine
02
Targets
VP4 (Rotavirus VP4)VP7 (Rotavirus VP7)
Beyond the preview
Go deeper on pentavalent reassortant rotavirus attenuated live vaccine (Sinovac Biotech).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pentavalent reassortant rotavirus attenuated live vaccine (Sinovac Biotech).